Evidence map›Paper›PMID 34830207›Full record

ReviewInternational journal of molecular sciences2021

Nuclear Receptors in Myocardial and Cerebral Ischemia-Mechanisms of Action and Therapeutic Strategies.

Joanna Rzemieniec, Laura Castiglioni, Paolo Gelosa, Majeda Muluhie, Benedetta Mercuriali, Luigi Sironi

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Pharmaceuticals (Basel, Switzerland) · 2026
    Article
  2. Review
  3. Nuclear Receptor ERRγ Protects Against Cardiac Ischemic Injury by Suppressing GBP5-Mediated Myocardial Inflammation.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  4. Review
  5. Article
  6. Review
  7. Aspects of xenobiotics and their receptors in stroke.Neuroprotection (Chichester, England) · 2023
    Review
  8. Article
  9. Review
  10. Review
  11. Polarization of Microglia and Its Therapeutic Potential in Sepsis.International journal of molecular sciences · 2022
    Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Joanna RzemieniecDepartment of Pharmaceutical Sciences, University of Milan, 20133 Milan, Italy.
Laura CastiglioniDepartment of Pharmaceutical Sciences, University of Milan, 20133 Milan, Italy.ORCID 0000-0002-0772-3231
Paolo GelosaDepartment of Pharmaceutical Sciences, University of Milan, 20133 Milan, Italy.
Majeda MuluhieDepartment of Pharmaceutical Sciences, University of Milan, 20133 Milan, Italy.
Benedetta MercurialiCentro Cardiologico Monzino IRCCS, 20138 Milan, Italy.
Luigi SironiDepartment of Pharmaceutical Sciences, University of Milan, 20133 Milan, Italy.ORCID 0000-0002-4738-3454
University of Milan · ITCentro Cardiologico Monzino · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nearly 18 million people died from cardiovascular diseases in 2019, of these 85% were due to heart attack and stroke. The available therapies although efficacious, have narrow therapeutic window and long list of contraindications. Therefore, there is still an urgent need to find novel molecular targets that could protect the brain and heart against ischemia without evoking major side effects. Nuclear receptors are one of the promising targets for anti-ischemic drugs. Modulation of estrogen receptors (ERs) and peroxisome proliferator-activated receptors (PPARs) by their ligands is known to exert neuro-, and cardioprotective effects through anti-apoptotic, anti-inflammatory or anti-oxidant action. Recently, it has been shown that the expression of aryl hydrocarbon receptor (AhR) is strongly increased after brain or heart ischemia and evokes an activation of apoptosis or inflammation in injury site. We hypothesize that activation of ERs and PPARs and inhibition of AhR signaling pathways could be a promising strategy to protect the heart and the brain against ischemia. In this Review, we will discuss currently available knowledge on the mechanisms of action of ERs, PPARs and AhR in experimental models of stroke and myocardial infarction and future perspectives to use them as novel targets in cardiovascular diseases.

Indexed as

AnimalsBasic Helix-Loop-Helix ProteinsBrain IschemiaDisease Models, AnimalHumansLigandsMiceMolecular Targeted TherapyMyocardial IschemiaPeroxisome Proliferator-Activated ReceptorsReceptors, Aryl HydrocarbonReceptors, EstrogenSelective Estrogen Receptor ModulatorsSignal TransductionStrokeTreatment OutcomeAHR protein, humanBasic Helix-Loop-Helix ProteinsLigandsPeroxisome Proliferator-Activated ReceptorsReceptors, Aryl HydrocarbonReceptors, EstrogenSelective Estrogen Receptor Modulatorsaryl hydrocarbon receptorbrainestrogen receptorsheartmyocardial infarctionperoxisome proliferator-activated receptorsselective aryl hydrocarbon receptor modulatorsselective estrogen receptor modulatorsstroke

Identifiers

PMID34830207
PMCPMC8617737
OpenAlexW3214675193

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.